fbpx

Excerpts from the publication

Methods: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure.

Results: Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. Conclusions: Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.

Read more

A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans

Miaoying Shi, Sebastiaan Wesseling, Hans Bouwmeester and Ivonne M. C. M. Rietjens
July 2021

The acute effects of classic psychedelics on memory in humans

C. J. Healy
January 2021

Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review

Alina Wilkowska, Mariusz S. Wiglusz, Katarzyna Jakuszkowiak-Wojten and Wiesław J. Cubała
February 2022

Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review

Jolien K E Veraart, MD, Sanne Y Smith-Apeldoorn, MD, Iris M Bakker, BSc, Berber A E Visser, BSc, Jeanine Kamphuis, MD, PhD, Robert A Schoevers, MD, PhD, Daan J Touw, PharmD
June 2021